"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": Reply

J Thromb Haemost. 2022 Aug;20(8):1937-1939. doi: 10.1111/jth.15774.

Trine-Lise Larsen^{1

2}, Herish Garresori³, Jorunn Brekke⁴, Tone Enden⁵, Hege Frøen⁶, Eva Marie Jacobsen⁷, Petter Quist-Paulsen⁸, Alina Carmen Porojnicu⁹, Anne Hansen Ree^{1

10}, Dag Torfoss¹¹, Elin Osvik Velle¹², Hilde Skuterud Wik⁷, Waleed Ghanima^{1

13}, Per Morten Sandset^{1

7}, Anders Erik Astrup Dahm^{1

2}

¹ Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
² Department of Hematology, Akershus University Hospital, Lørenskog, Norway.
³ Department of Oncology, Stavanger University Hospital, Stavanger, Norway.
⁴ Department of Oncology, Haukeland University Hospital, Bergen, Norway.
⁵ Department of Radiology, Oslo University Hospital, Oslo, Norway.
⁶ Department of Medicine, Baerum Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
⁷ Department of Hematology, Oslo University Hospital, Oslo, Norway.
⁸ Department of Hematology, St. Olav's University Hospital, Trondheim, Norway.
⁹ Department of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
¹⁰ Department of Oncology, Akershus University Hospital, Lørenskog, Norway.
¹¹ Department of Oncology, Oslo University Hospital, Oslo, Norway.
¹² Department of Medicine, Volda Hospital, Møre and Romsdal Hospital Trust Volda, Ålesund, Norway.
¹³ Clinic of Internal Medicine, Østfold Hospital, Grålum, Norway.

No abstract available

Publication types